Initiator Pharma A/S, a clinical-stage biotech company, today announced that the company has decided to focus fully on its most promising drug candidate, pudafensine, which is being developed for both vulvodynia and organic erectile dysfunction (ED). As part of this prioritization, the company will discontinue further development of IP2018.
“We are encouraged by the opportunities for pudafensine across multiple indications. With already strong Phase IIb proof-of-concept data for pudafensine in organic erectile dysfunction, we now hope to obtain additional proof-of-concept data in vulvodynia from our ongoing Phase IIa clinical study before the end of the year,” said Claus Elsborg Olesen, CEO of Initiator Pharma. “By focusing our resources on this asset, we aim to maximize value creation and accelerate its path toward commercialization.”
Pudafensine is an orally administered drug candidate with a unique dual mechanism of action targeting both central pain regulation and sexual function. It is is being developed for the treatment of organic erectile dysfunction, vulvodynia, female sexual dysfunction and certain pain indications.
The compound is currently being evaluated in a Phase IIa clinical proof-of-concept study in women suffering from vulvodynia, which is expected to be completed by the end of 2026. Pudafensine has the potential to improve the quality of life for millions of patients who do not respond to, or cannot be treated with, currently available therapies.
“In our discussions with potential partners, we have observed the strongest interest in pudafensine, supported by its clinical data package and favorable safety profile,” added Claus Elsborg Olesen. “This strategic focus enables a more efficient allocation of resources and strengthens our ability to advance our most promising asset.”
As a consequence, Initiator Pharma will discontinue further development of IP2018 for psychogenic erectile dysfunction. Resources previously allocated to IP2018 will be redirected to the continued development of pudafensine.